<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856970</url>
  </required_header>
  <id_info>
    <org_study_id>C3718-103</org_study_id>
    <nct_id>NCT03856970</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel, Sequential, Multi-part Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of an Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are the following:

        -  To evaluate the pharmacokinetics (PK) of a monophasic oral contraceptive's active
           components, ethinyl estradiol (EE) and norethindrone acetate (NET), following a single
           oral dose alone and in combination with IW-3718 in healthy adult female participants.

        -  To evaluate the PK of levothyroxine following a single oral dose alone and in
           combination with IW-3718 in healthy adult participants.

        -  To evaluate the PK of glyburide following a single oral dose alone and in combination
           with IW-3718 in healthy adult participants.

        -  To evaluate the PK of digoxin following a single oral dose alone and in combination with
           IW-3718 in healthy adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Actual">July 3, 2019</completion_date>
  <primary_completion_date type="Actual">June 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK of EE and NET: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Last Quantifiable Concentration (AUC0-t)</measure>
    <time_frame>Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of EE and NET: AUC From Time 0 Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of EE and NET: Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of EE and NET: Time to Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of EE and NET: Terminal Phase Half-Life (t1/2)</measure>
    <time_frame>Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Levothyroxine: AUC0-t</measure>
    <time_frame>Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Levothyroxine: AUC0-inf</measure>
    <time_frame>Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Levothyroxine: Cmax</measure>
    <time_frame>Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Levothyroxine: Tmax</measure>
    <time_frame>Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Levothyroxine: t1/2</measure>
    <time_frame>Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Glyburide: AUC0-t</measure>
    <time_frame>Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Glyburide: AUC0-inf</measure>
    <time_frame>Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Glyburide: Cmax</measure>
    <time_frame>Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Glyburide: Tmax</measure>
    <time_frame>Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Glyburide: t1/2</measure>
    <time_frame>Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Digoxin: AUC0-t</measure>
    <time_frame>Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Digoxin: AUC0-inf</measure>
    <time_frame>Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Digoxin: Cmax</measure>
    <time_frame>Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Digoxin: Tmax</measure>
    <time_frame>Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of Digoxin: t1/2</measure>
    <time_frame>Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations due to TEAEs</measure>
    <time_frame>Part 1: up to Day 27 (±1 day); Part 2: up to Day 49 (±1 day); Part 3: Day 50 (±1 day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ≥1 Clinically Significant Changes in Clinical Laboratory Test Results</measure>
    <time_frame>Part 1: up to Day 19; Part 2: up to Day 41; Part 3: up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ≥1 Clinically Significant Changes in Vital Sign Measurements</measure>
    <time_frame>Part 1: up to Day 19; Part 2: up to Day 41; Part 3: up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ≥1 Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Results</measure>
    <time_frame>Part 1: up to Day 19; Part 2: up to Day 41; Part 3: up to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ≥1 Clinically Significant Changes in Physical Examination Findings</measure>
    <time_frame>Part 1: up to Day 19; Part 2: up to Day 41; Part 3: up to Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1: Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microgestin® (EE 30 μg and NET 1500 μg) single dose (Day 1). After a 10-14 day washout, Microgestin® single dose (Day 14) PLUS IW-3718 1500 mg twice daily (Days 13 to 19).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levothyroxine 600 μg single dose (Day 1). After a 35-39 day washout, levothyroxine 600 μg single dose (Day 39) PLUS IW-3718 1500 mg twice daily (Days 38 to 41).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Glyburide 5 mg single dose (Day 1). After a 7-10 day washout, glyburide 5 mg single dose (Day 11) PLUS IW-3718 1500 mg twice daily (ie, Days 10 to 14).
Phase 2: Digoxin 0.25 mg single dose (Day 23). After a 10-14 day washout, digoxin 0.25 mg mg single dose (Day 35) PLUS IW-3718 1500 mg twice daily (Days 34 to 42).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microgestin®</intervention_name>
    <description>30 μg/1500 μg tablets for oral administration</description>
    <arm_group_label>Part 1: Healthy Volunteers</arm_group_label>
    <other_name>ethinyl estradiol 30 μg and norethindrone 1500 μg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>600 μg tablets for oral administration</description>
    <arm_group_label>Part 2: Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide</intervention_name>
    <description>5 mg tablets for oral administration</description>
    <arm_group_label>Part 3: Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>0.25 mg tablets for oral administration</description>
    <arm_group_label>Part 3: Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-3718</intervention_name>
    <description>500-mg film-coated tablets for oral administration</description>
    <arm_group_label>Part 1: Healthy Volunteers</arm_group_label>
    <arm_group_label>Part 2: Healthy Volunteers</arm_group_label>
    <arm_group_label>Part 3: Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is healthy, ambulatory, and 18-50 years of age (inclusive) at screening visit.

          -  Weighs at least 50 kg and has a body mass index within 18-35 kg/m2 at the screening
             visit.

          -  Is not pregnant or breastfeeding at the time of the screening visit and has negative
             serum pregnancy tests at the screening visit and check-in.

          -  Other inclusion criteria per protocol.

        Exclusion Criteria:

          -  Has used any prescription drugs, herbal supplements, over-the-counter medication, or
             dietary supplements (vitamins included) within 4 weeks prior to dosing. If needed,
             (ie, incidental and limited need), acetaminophen is acceptable.

          -  Has consumed grapefruit or grapefruit juice within 4 weeks prior to dosing or plans to
             consume grapefruit or grapefruit juice before 7 days following the last dose.

          -  Has a significant illness that has not resolved within 2 weeks prior to dosing.

          -  Has a history of immunodeficiency diseases, including a positive human
             immunodeficiency virus test result.

          -  Has a positive hepatitis B surface antigen or hepatitis C antibody test result.

          -  Is a smoker or has used nicotine or nicotine-containing products (eg, snuff, nicotine
             patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the
             first dose of study drug.

          -  Other exclusion criteria per protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zurab Machaidze, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ironwood Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

